+

WO2007067780A3 - Thérapie combinee et panneaux d'anticorps - Google Patents

Thérapie combinee et panneaux d'anticorps Download PDF

Info

Publication number
WO2007067780A3
WO2007067780A3 PCT/US2006/047077 US2006047077W WO2007067780A3 WO 2007067780 A3 WO2007067780 A3 WO 2007067780A3 US 2006047077 W US2006047077 W US 2006047077W WO 2007067780 A3 WO2007067780 A3 WO 2007067780A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
combination immunotherapy
combination therapy
idiotypic
administration
Prior art date
Application number
PCT/US2006/047077
Other languages
English (en)
Other versions
WO2007067780A2 (fr
Inventor
Dan W Denney
Keri Marie Tate
Thomas P Theriault
Original Assignee
Genitope Corp
Dan W Denney
Keri Marie Tate
Thomas P Theriault
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/297,167 external-priority patent/US20070134248A1/en
Priority claimed from US11/297,168 external-priority patent/US20070134249A1/en
Application filed by Genitope Corp, Dan W Denney, Keri Marie Tate, Thomas P Theriault filed Critical Genitope Corp
Priority to CA002632744A priority Critical patent/CA2632744A1/fr
Publication of WO2007067780A2 publication Critical patent/WO2007067780A2/fr
Publication of WO2007067780A3 publication Critical patent/WO2007067780A3/fr
Priority to GB0812408A priority patent/GB2448627B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une immunothérapie combinée pour des cellules malignes de type lymphome non Hodgkinien (LNH) et leucémie lymphocytique chronique (LLC). Dans un mode de réalisation, l'immunothérapie combinée consiste d’abord à administrer un anticorps monoclonal, ou un fragment d'anticorps, dirigé contre une partie non idiotypique d'une immunoglobuline ou d’une molécule semblable à une immunoglobuline exprimée sur la surface d'une cellule maligne (par exemple, une région de structure d'une région variable). L'immunothérapie combinée consiste ensuite à administrer une composition immunogénique qui comprend au moins une partie de la même immunoglobuline de surface de la cellule maligne, que ce soit une partie idiotypique ou partie non idiotypique.
PCT/US2006/047077 2005-12-08 2006-12-08 Thérapie combinee et panneaux d'anticorps WO2007067780A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002632744A CA2632744A1 (fr) 2005-12-08 2006-12-08 Therapie combinee et panneaux d'anticorps
GB0812408A GB2448627B (en) 2005-12-08 2008-07-07 Combination therapy and antibody panels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/297,168 2005-12-08
US11/297,167 2005-12-08
US11/297,167 US20070134248A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels
US11/297,168 US20070134249A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels

Publications (2)

Publication Number Publication Date
WO2007067780A2 WO2007067780A2 (fr) 2007-06-14
WO2007067780A3 true WO2007067780A3 (fr) 2008-05-02

Family

ID=38123554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047077 WO2007067780A2 (fr) 2005-12-08 2006-12-08 Thérapie combinee et panneaux d'anticorps

Country Status (3)

Country Link
CA (1) CA2632744A1 (fr)
GB (1) GB2448627B (fr)
WO (1) WO2007067780A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922212B1 (fr) * 2007-10-11 2011-11-11 France Etat Anticorps anti ricine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVIS ET AL.: "Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradication the Malignant Clone", BLOOD, vol. 92, August 1998 (1998-08-01), pages 1184 - 1190 *
NELSON ET AL.: "Tumor - Specific, Cytotoxic T-Lymphocyte Response After Idiotype Vaccination for B-cell, Non-Hodgkin's Lymphoma", BLOOD, vol. 88, July 1996 (1996-07-01), pages 580 - 589 *
RUFFINI ET AL.: "Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines", HAEMATOLOGICA, vol. 87, September 2002 (2002-09-01), pages 989 - 1001 *

Also Published As

Publication number Publication date
WO2007067780A2 (fr) 2007-06-14
GB2448627B (en) 2010-07-14
CA2632744A1 (fr) 2007-06-14
GB0812408D0 (en) 2008-08-13
GB2448627A (en) 2008-10-22

Similar Documents

Publication Publication Date Title
ATE535547T1 (de) Vernetzte antikörper
WO2005000901A3 (fr) Anticorps specifiques de cd20 et leurs methodes d'utilisation
WO2008053330A3 (fr) Anticorps monoclonaux et fragments de ceux-ci dirigés contre le récepteur de type ii de l'hormone antimüllérienne humaine (amhr-ii)
WO2003072036A3 (fr) Methodes therapeutiques utilisant des anticorps anti-cd22
WO2004078938A3 (fr) Polypeptides et anticorps derives de cellules de leucemie lymphocytique chronique et utilisations correspondantes
WO2005010048A3 (fr) Anticorps de rg1 et utilisation de ceux-ci
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
WO2005115452A3 (fr) Anticorps specifiques de fc$g(g)rii et methodes d'utilisation de ces anticorps
WO2003048328A3 (fr) Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
WO2007000671A3 (fr) Anticorps monoclonaux anti-cd71 et leurs utilisations pour le traitement de cellules tumorales malignes
ATE513857T1 (de) Zelloberflächenglycoproteinen aus eierstockkrebs- zellen und myeloma zellen , deren antikörper und verwendungen davon
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
DE602005016773D1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
WO2004094473A3 (fr) Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
WO2004010947A3 (fr) Anticorps humanises contre le 4-1bb humain
WO2008070042A3 (fr) Anticorps recombinants de forte puissance, procédé pour leur production et utilisation en thérapie contre le cancer
WO2008098917A3 (fr) Nouveaux anticorps
WO2006076525A3 (fr) Therapie du cancer de combinaison avec des anticorps diriges contre l'antigene membranaire specifique de la prostate
WO2007075921A3 (fr) Antigenes d'acide sialique des-n-acetyle, leurs anticorps et leurs methodes d'utilisation dans des therapies anticancereuses
WO2004035742A3 (fr) Ensembles d'anticorps numeriques diriges contre des epitopes courts et leurs methodes d'utilisation
WO2008100563A3 (fr) Compositions et méthodes pour diagnostiquer et traiter le cancer
WO2005000207A3 (fr) Anticorps du recepteur du pcdgf et procede d'utilisation associe
WO2009126817A3 (fr) Anticorps d'ige pour le traitement du cancer
WO2007067780A3 (fr) Thérapie combinee et panneaux d'anticorps
WO2004113388A3 (fr) Anticorps monoclonaux se liant specifiquement a un antigene tumoral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2632744

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 0812408.3

Country of ref document: GB

Ref document number: 812408

Country of ref document: GB

Ref document number: 0812408

Country of ref document: GB

122 Ep: pct application non-entry in european phase

Ref document number: 06845134

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载